Abstract
Background
To tackle the growing allergy epidemic, novel therapeutic approaches are urgently needed. One promising avenue is the development of anti-allergen antibody therapies. This passive immunization approach stands out from traditional allergen immunotherapy by not exposing patients to the allergen but also by potentially treating patients who are less responsive or even unresponsive to allergen immunotherapies and providing immediate protection.
Methods
After a review of historical and recently published literature on the topic of anti-allergen antibodies, the status quo and recent advancements are presented. Anti-allergen antibody therapies in the context of immunological changes that occur during allergen immunotherapy are also discussed.
Results
While the protective role of anti-allergen antibodies was recognized decades ago, the advancement of antibody discovery technologies has fueled the field, and now different anti-allergen antibody therapies are approaching clinical use. These developments have also broadened our understanding of the allergens and allergenic epitopes responsible in different allergic diseases, and also the role played by immunoglobulins in shaping the immune system.
Conclusion
The development of anti-allergen antibody therapies offers great potential for the treatment of allergies. Of interest, the efficacy of passive immunization approaches will likely extend beyond allergen neutralization as in the presence of the allergen they might contribute to long-lasting disease modification.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
With the prevalence of allergies increasing worldwide, there is an urgent need to find novel therapies for allergic patients. Over the last few decades, allergen immunotherapy (AIT) has been an important treatment option in both food and environmental allergies and is the only disease-modifying therapy available to date. However, limitations remain in terms of AIT efficacy, safety, and treatment regimen, which entails that important segments of the allergic patient population do not have access to effective therapies. Thus, the administration of allergen-specific neutralizing antibodies provides a novel, promising treatment for allergies.
Protective role of anti-allergen IgG in allergic disease
One of the main immunological changes during allergen immunotherapy, observed over 50 years ago, is an increase in allergen-specific IgGs, followed by a decrease in allergen-specific IgE levels [1]. Elevated levels of anti-allergen IgGs have also been discovered in beekeepers, a population repetitively exposed to the bee venom allergen, albeit protected from venom allergic reactions [2]. Based on these observations it has been postulated that allergen-specific IgGs compete with IgEs for binding to the allergen, thus, preventing allergen-mediated cross-linking of allergen-specific IgE bound on basophils and mast cells and hence cell degranulation. One of the first studies to confirm the protective role of anti-allergen IgGs showed that blood transfusion or sera injections from patients successfully desensitized from hay fever to allergic patients were able to transfer protection [3]. Similarly, the plasma of hyperimmune beekeepers allowed bee venom allergic patients to tolerate 1.5–5 times the venom dose that had previously elicited an allergic response [4]. While these studies have proven the protective role of anti-allergen immunoglobulins, it was later shown that anti-allergen IgG antibody levels, even though consistently increased in patients undergoing AIT, do not always correlate with successful desensitization [5]. It has been speculated that this is due to the different epitope specificity of IgG induced by allergen immunotherapy in successfully desensitized individuals compared to nonresponders. Indeed, functional IgE competition with IgGs induced during AIT has been shown to better correlate with successful desensitization [6]. These studies concluded that the formation of blocking antibodies that neutralize the allergen, thereby preventing allergen binding to IgE on allergic effector cells, are crucial for successful disease modification towards allergen tolerance/unresponsiveness and in raising the threshold for allergen reactivity. In line with this, monoclonal antibodies (mAbs) cloned from peanut-allergic patients who showed sustained unresponsiveness after withdrawal from AIT were shown to target slightly different epitopes on the major peanut allergen Ara h 2 than mAbs from patients who showed only transient desensitization [7, 8]. Immunoglobulin responses are one of the many different immunological changes that occur during immunotherapy, which also include modulation of specific T‑cell subsets. For example, in peanut allergic individuals, successful AIT was associated with suppression of T helper cells 2A (TH2A), a subset of T helper cells uniquely found in allergic individuals [9, 10]. Interestingly T-follicular-cell subsets, important to induce IgE class switch, were shown to be more resistant to changes induced by AIT. These data highlight the challenges of inducing durable immune tolerance that blocks pathogenic IgE formation and increases protective IgGs. In conclusion, IgG/IgE ratios and the increase of allergen-neutralizing IgGs remain the best serological predictors of protection from allergic disease. Thus, the clinical use of anti-allergen neutralizing IgG antibodies has great potential and rationale for being developed as novel therapies.
Advancements in antibody discovery technologies
Early attempts to use anti-allergen antibodies, or allergen passive immunization, were, however, limited in their clinical applicability. Indeed, passive transfer of plasma encounters the same limitations observed for the use of hyperimmune sera in infectious diseases, as seen recently in the treatment of COVID-19: product variability, logistic hurdles, and even more importantly low antigen-specific antibody titers important for effective, lasting antigen neutralization [11]. Nevertheless, technological progress in the last decade created the right environment for the development of passive immunotherapies against allergens in a novel, targeted, and controlled way. Particularly important was the booming field of antibody discovery technologies that enabled the efficient isolation, cloning, and expression of allergen-specific antibody libraries [12].
Different technologies have been applied to discover anti-allergen antibodies. For example, animal immunizations have been used to clone such antibodies. This technology was described by Atanasio, Orengo, and colleagues for raising anti-Fel d 1 and anti-Bet v 1 antibodies for cat and birch allergy, respectively [13, 14]. These researchers used their proprietary platform of transgenic mice harboring human immunoglobulin loci, thus, overcoming the need to humanize antibodies and streamlining antibody development. In an alternative approach, we and other researchers have instead focused on the isolation of anti-allergen antibodies directly from allergic patients. This approach has the added benefit of isolating antibodies against the immunodominant allergens and epitopes that are mediating the disease in patients, thus, increasing the likelihood of isolating functionally neutralizing antibodies. One of the technologies used for patient-derived antibody discovery is phage display, with random heavy and light chain pairings. This approach has led to the isolation, for example, of antibodies from patients vaccinated with hypoallergenic Bet v 1 fragments [15]. Recent years have seen an increased use of single-cell technologies applied to B cells. The advantage of B‑cell screening is that it maintains the cognate heavy and light chain antibody pairing, preserving those favorable properties that have been selected by the human immune systems in terms of affinity, specificity, and biophysical properties [12]. Single B‑cell screening technologies have been used to isolate potent neutralizing antibodies against peanut allergens [8, 16, 17]. The concomitant advent of antibody repertoire sequencing technologies has also increased our understanding of anti-allergen antibody repertoire diversity and evolution. Interestingly, different studies described that some immunodominant allergenic epitopes force selected V(D)J combinations resulting in convergent evolution of antibody germlines [17, 18].
Choosing the memory B-cell source to clone human-derived anti-allergen mAbs
IgE B cells are extremely rare and the current model states that IgE-secreting cells are continuously generated from IgG B-cell precursors in the presence of the appropriate microenvironment [19]. This is also supported by the overall similar epitope coverage observed between IgE and IgG from allergic patients, and the clonal relationship between the rare IgE B cells and IgG memory B cells [20, 21]. Part of the IgE serological memory could come from rare circulating IgE plasmablasts or bone marrow resident long-lived plasma cells [17, 22]. However, it is likely that the majority of the IgE response occurs in the disease-relevant tissue by locally switching from IgG memory B cells, for example, in the gut in peanut allergic patients [23]. It is still unclear whether the switch from IgG to IgE is mainly driven by extrinsic factors, such as the cytokine milieu, or an intrinsic property of a subset of memory IgG B cells. The recent description of a CD23-expressing memory B-cell subset that is prone to IgE switching supports, at least in part, the importance of intrinsic factors [24, 25]. The overlap between IgG and IgE memory B-cells repertoires is also corroborated by findings by us and others that antibodies derived from IgG memory B cells are able to compete with a patient’s IgE binding to the major allergens [8, 16]. Overall, in parallel to their therapeutic potential, development of patient-derived anti-allergen therapeutics is also improving our understanding of allergy antibody responses and their clinical relevance.
Neutralizing allergens with antibody cocktails
An important finding driven by the recent developments of anti-allergen antibody therapies is that a limited number of antibodies can significantly compete with most patient-derived IgE, outside the patient pool from which these antibodies were derived, thus, demonstrating the dominance of the targeted epitopes and allergens [13, 14, 16]. This property allows for the development of anti-allergen antibody therapies, as an excessive number of antibodies would be challenging due to manufacturing, regulatory, and pharmacoeconomic hurdles. It is interesting in this respect that all the anti-allergen therapies being developed so far have been applied to allergies in which one major allergen has been postulated such as cat and birch allergy, with respectively Fel d 1 and Bet v 1 as potentially the unique major allergens driving the disease [13, 14]. While efforts move to tackle allergies where more than one major allergen has been described, it will be interesting to see how researchers in this field can develop a limited number of monoclonal antibodies while targeting as broadly as possible the disease-driving allergens and epitopes. One approach to circumvent the development and manufacturing of multiple single mAbs is to directly manufacture antibody cocktails in a single bioreactor batch by co-expression from mixture of different cell lines. This production method, which enables the creation of complex antibody mixtures, has recently been utilized to produce a recombinant polyclonal mixture of up to 25 different mAbs [26]. By employing this approach, even complex allergies caused by a larger number of allergens and allergenic epitopes could be treated through passive immunotherapy. Yet, this approach remains challenging in terms of chemistry, manufacturing, and controls (CMC) aspects and regulatory requirements. Alternatively, the number of different antibody molecules can be reduced by combining several V regions into bispecific or even multispecific molecules. Over the past few decades, advances in antibody engineering technologies have greatly facilitated the construction of such molecules [27, 28]. While this approach may significantly reduce production costs and streamline the regulatory process, it may also likely require considerable development efforts.
Anti-allergen antibodies efficacy: beyond simple neutralization
It is not unlikely that another enabling factor in the development of anti-allergen therapies is represented by the increased use and understanding of passive immunization approaches made in infectious diseases. Use of monoclonal antibodies against Ebola and SARS-CoV‑2 have showcased the potential of the passive immunotherapy approach. In addition, the use of monoclonal antibodies during the SARS-CoV‑2 pandemic has highlighted that antibody efficacy in restricting infection goes beyond simple neutralization and competition with cellular virus receptors [29]. Effector function, antigen presentation, and restriction of viral replication are all antibody-mediated mechanisms that work together to prevent pathogen spread [29]. Similarly, anti-allergen antibody therapies are expected to exhibit a range of additional modes of action beyond neutralization (Fig. 1), albeit this is likely to remain the main mechanism of action.
These additional modes of action, together with its association with protection from allergic disease in patients, are likely the reason why IgG4 was selected as the backbone of anti-allergen antibody therapeutics. As opposed to IgG1 with effector-incompetent Fc regions often used in other antibody therapeutics [8, 13, 14, 16, 17], IgG4 still retains binding to a subset of immunoglobulin receptors. In addition, IgG4 shows lower complement activation, which provides an improved safety profile when compared to effector-competent IgG1 [30]. Most importantly, IgG4 maintains binding to the Fcγ receptor IIB (FcγRIIB also known as CD32B) which plays a crucial role in modulating the allergic response. FcγRIIB is the only receptor containing the immune tyrosine inhibitory motif (ITIM) and can suppress mast cell and basophil activation [31]. This suppressive activity is thought to be an important mechanism of action of IgG during allergen desensitization. However, it is difficult to dissect the relative contribution of IgG between allergen neutralization or by FcγRIIB engagement in patients. In cellular assays, blocking FcγRIIB has been shown to impair efficacy of anti-allergen antibodies [32]. In mouse studies, the evidence is less consistent as it has been both shown that anti-allergen antibodies have decreased efficacy when blocking FcγRIIB but in other instances retain efficacy without a functional Fc, suggesting that at least in certain circumstances neutralization plays a key role [16, 33].
However, natural IgG4 are unique in their ability to undergo Fab arm exchange in circulation, which randomly combines two IgG4 halves making IgG4 de facto monovalent and bispecific in patients [34]. This monovalency also decreases the likelihood to form immune complexes, which is one of their anti-inflammatory properties To avoid having a heterogenous product with uncontrollable Fab arm exchange in patients, the hinge region of therapeutic IgG4 is generally modified to completely abolish Fab arm exchange [35].
Potential immunomodulatory role of anti-allergen antibodies
Regardless of the relative importance of FcγRIIB receptor in driving the therapeutic response to anti-allergen antibodies, retaining some effector function might be beneficial for the potential of combining anti-allergen antibody therapies with AIT, i.e., passive and active immunotherapy. This is especially attractive in food immunotherapy for which side effects are significant and a major barrier to their wider uptake. Early approaches utilizing hyperimmune serum tested this hypothesis clinically in both ragweed-allergic patients and honeybee venom-allergic patients. Administration of hyperimmune sera allowed to reach 10-fold higher allergen doses during rush desensitization protocols, while at the same time maintaining induction of allergen specific IgGs [36, 37]. In addition, Burton and colleagues found that FcγRIIB plays a significant role in inducing desensitization and a tolerogenic T‑cell response in a mouse model of combination therapy of anti-allergen antibodies with AIT [38]. This effect was correlated with decreased degranulation and suppression of IL‑4 secretion likely from FcγRIIB expressing cells, and was concomitant with an increase in anti-inflammatory T regulatory cells. It is possible that another contributing factor to increased tolerance induction in the presence of anti-allergen antibodies will be driven by an effect on antigen presentation. Anti-allergen antibodies will block facilitated allergen presentation by B cells through IgE:FcεRII [39, 40]. On the other hand, anti-allergen IgGs might shift allergen presentation to the myeloid compartment through Fc-mediated receptors which, in the context of a different cytokine milieu, could promote induction of tolerance by engagement of different T‑cell subsets. A similar immunomodulatory role of anti-allergen IgGs has been shown for maternal IgG [41]. In general, anti-allergen IgG could promote tolerance induction or a state of sustained unresponsiveness, while protecting against side-effects and simplifying AIT clinical protocols, as observed in the earlier clinical studies with hyperimmune serum [36, 37].
Conclusion
Overall, fueled by novel antibody discovery technologies, anti-allergen antibody therapies are now being developed that are likely to change the therapy landscape of allergies as they progress through clinical testing. Anti-allergen antibody therapy, or passive immunization, has the potential to quickly and safely protect against allergic reactions, while reaching a bigger population of allergic patients currently excluded from AIT. In addition, the contribution of anti-allergen antibodies, when combined with the allergen or with AIT, in inducing tolerance offers a unique opportunity to immediately protect patients while working on permanent disease modification.
Abbreviations
- AIT:
-
Allergen immunotherapy
- CMC:
-
Chemistry, manufacturing, and controls aspects
- ITIM:
-
Immune tyrosine inhibitory motif
- mAbs:
-
Monoclonal antibodies
References
Devey ME, Wilson DV, Wheeler AW. The IgG subclasses of antibodies to grass pollen allergens produced in hay fever patients during hyposensitization. Clin Exp Allergy. 1976;6:227–36. https://doi.org/10.1111/j.1365-2222.1976.tb01901.x.
Varga E‑M, Kausar F, Aberer W, Zach M, Eber E, Durham SR, et al. Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE. J Allergy Clin Immunol. 2013;131:1419–21. https://doi.org/10.1016/j.jaci.2012.08.037.
Cooke RA, Barnard JH, Hebald S, Stull A. Serological evidence of immunity with coexisting sensitization in a type of human allergy (Hay fever). J Exp Med. 1935;62:733–50. https://doi.org/10.1084/jem.62.6.733.
Lessof MH, Sobotka AK, Lichtenstein LM. Effects of passive antibody in bee venom anaphylaxis. Johns Hopkins Med J. 1978;142:1–7.
Jarolim E, Poulsen LK, Stadler BM, Mosbech H, Oesterballe O, Kraft D, et al. A long-term follow-up study of hyposensitization with immunoblotting. J Allergy Clin Immunol. 1990;85:996–1004. https://doi.org/10.1016/0091-6749(90)90043-4.
James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN, et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol. 2011;127:509–516.e5. https://doi.org/10.1016/j.jaci.2010.12.1080.
Shamji MH, Ljørring C, Francis JN, A Calderon M, Larché M, Kimber I, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy: Functional IgG4 correlates with clinical efficacy of allergen specific immunotherapy. Allergy. 2012;67:217–26. https://doi.org/10.1111/j.1398-9995.2011.02745.x.
LaHood NA, Min J, Keswani T, Richardson CM, Amoako K, Zhou J, et al. Immunotherapy-induced neutralizing antibodies disrupt allergen binding and sustain allergen tolerance in peanut allergy. J Clin Investig. 2023;133:e164501. https://doi.org/10.1172/JCI164501.
Monian B, Tu AA, Ruiter B, Morgan DM, Petrossian PM, Smith NP, et al. Peanut oral immunotherapy differentially suppresses clonally distinct subsets of T helper cells. J Clin Investig. 2022;132:e150634. https://doi.org/10.1172/JCI150634.
Wambre E, Bajzik V, DeLong JH, O’Brien K, Nguyen Q‑A, Speake C, et al. A phenotypically and functionally distinct human T H 2 cell subpopulation is associated with allergic disorders. Sci Transl Med. 2017;9:eaam9171. https://doi.org/10.1126/scitranslmed.aam9171.
Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021;325:1185. https://doi.org/10.1001/jama.2021.2747.
Pedrioli A, Oxenius A. Single B cell technologies for monoclonal antibody discovery. Trends Immunol. 2021;42:1143–58. https://doi.org/10.1016/j.it.2021.10.008.
Atanasio A, Franklin MC, Kamat V, Hernandez AR, Badithe A, Ben L‑H, et al. Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the birch allergic response. J Allergy Clin Immunol. 2022;149:200–11. https://doi.org/10.1016/j.jaci.2021.05.038.
Orengo JM, Radin AR, Kamat V, Badithe A, Ben LH, Bennett BL, et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. Nat Commun. 2018;9:1421. https://doi.org/10.1038/s41467-018-03636-8.
Gadermaier E, Marth K, Lupinek C, Campana R, Hofer G, Blatt K, et al. Isolation of a high-affinity Bet v 1‑specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments. Allergy. 2018;73:1425–35. https://doi.org/10.1111/all.13394.
Paolucci M, Wuillemin N, Homère V, Bieli D, Köhli A, Ballmer-Weber B, et al. Targeting Ara h 2 with human-derived monoclonal antibodies prevents peanut-induced anaphylaxis in mice. Allergy. 2023; https://doi.org/10.1111/all.15659.
Croote D, Darmanis S, Nadeau KC, Quake SR. High-affinity allergen-specific human antibodies cloned from single IgE B cell transcriptomes. Science. 2018;362:1306–9. https://doi.org/10.1126/science.aau2599.
Patil SU, Ogunniyi AO, Calatroni A, Tadigotla VR, Ruiter B, Ma A, et al. Peanut oral immunotherapy transiently expands circulating Ara h 2–specific B cells with a homologous repertoire in unrelated subjects. J Allergy Clin Immunol. 2015;136:125–134.e12. https://doi.org/10.1016/j.jaci.2015.03.026.
Hoof I, Schulten V, Layhadi JA, Stranzl T, Christensen LH, De La Herrera Mata S, et al. Allergen-specific IgG+ memory B cells are temporally linked to IgE memory responses. J Allergy Clin Immunol. 2020;146:180–91. https://doi.org/10.1016/j.jaci.2019.11.046.
Chen G, Shrock EL, Li MZ, Spergel JM, Nadeau KC, Pongracic JA, et al. High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy. Cell Rep Med. 2021;2:100410. https://doi.org/10.1016/j.xcrm.2021.100410.
Looney TJ, Lee J‑Y, Roskin KM, Hoh RA, King J, Glanville J, et al. Human B‑cell isotype switching origins of IgE. J Allergy Clin Immunol. 2016;137:579–586.e7. https://doi.org/10.1016/j.jaci.2015.07.014.
Asrat S, Kaur N, Liu X, Ben L‑H, Kajimura D, Murphy AJ, et al. Chronic allergen exposure drives accumulation of long-lived IgE plasma cells in the bone marrow, giving rise to serological memory. Sci Immunol. 2020;5:eaav8402. https://doi.org/10.1126/sciimmunol.aav8402.
Hoh RA, Joshi SA, Lee J‑Y, Martin BA, Varma S, Kwok S, et al. Origins and clonal convergence of gastrointestinal IgE + B cells in human peanut allergy. Sci Immunol. 2020;5:eaay4209. https://doi.org/10.1126/sciimmunol.aay4209.
Koenig JFE, Knudsen NPH, Phelps A, Bruton K, Hoof I, Lund G, et al. A distinct phenotype of polarized memory B cell holds IgE memory. Immunology. 2023; https://doi.org/10.1101/2023.01.25.525495.
Ota M, Hoehn KB, Ota T, Aranda CJ, Friedman S, Braga WF, et al. The memory of pathogenic IgE is contained within CD23 + IgG1 + memory B cells poised to switch to IgE in food allergy. Immunology. 2023; https://doi.org/10.1101/2023.01.25.525506.
Robak T, Windyga J, Trelinski J, Von Depka Prondzinski M, Giagounidis A, Doyen C, et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood. 2012;120:3670–6. https://doi.org/10.1182/blood-2012-06-438804.
Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67:95–106. https://doi.org/10.1016/j.molimm.2015.01.003.
Brinkmann U, Kontermann RE. The making of bispecific antibodies. mAbs. 2017;9:182–212. https://doi.org/10.1080/19420862.2016.1268307.
Gupta R, Purcell LA, Corti D, Virgin HW. Pandemic preparedness strategies must go beyond vaccines. Sci Transl Med. 2023;15:eadd3055. https://doi.org/10.1126/scitranslmed.add3055.
Liu R, Oldham R, Teal E, Beers S, Cragg M. Fc-engineering for modulated effector functions—Improving antibodies for cancer treatment. Antibodies. 2020;9:64. https://doi.org/10.3390/antib9040064.
Daëron M, Malbec O, Latour S, Arock M, Fridman WH. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest. 1995;95:577–85. https://doi.org/10.1172/JCI117701.
Burton OT, Logsdon SL, Zhou JS, Medina-Tamayo J, Abdel-Gadir A, Noval Rivas M, et al. Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE-mediated hypersensitivity. J Allergy Clin Immunol. 2014;134:1310–1317.e6. https://doi.org/10.1016/j.jaci.2014.05.042.
Strait RT, Morris SC, Finkelman FD. IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking. J Clin Invest. 2006;116:833–41. https://doi.org/10.1172/JCI25575.
Van Der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic fab arm exchange. Science. 2007;317:1554–7. https://doi.org/10.1126/science.1144603.
Rispens T, Huijbers MG. The unique properties of IgG4 and its roles in health and disease. Nat Rev Immunol. 2023; https://doi.org/10.1038/s41577-023-00871-z.
Bernstein IL, Michael JG, Malkiel S, Sweet LC, Brackett RG. Immunoregulatory function of specific IgG. II. Clinical evaluation of combined active and passive immunotherapy. Int Arch Allergy Appl Immunol. 1979;58:30–7.
Bousquet J, Fontez A, Aznar R, Robinet-Levy M, Michel FB. Combination of passive and active immunization in honeybee venom immunotherapy. J Allergy Clin Immunol. 1987;79:947–54. https://doi.org/10.1016/0091-6749(87)90245-4.
Burton OT, Tamayo JM, Stranks AJ, Koleoglou KJ, Oettgen HC. Allergen-specific IgG antibody signaling through FcγRIIb promotes food tolerance. J Allergy Clin Immunol. 2018;141:189–201.e3. https://doi.org/10.1016/j.jaci.2017.03.045.
van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol. 1999;163:2944–52.
van der Heijden FL, Joost van Neerven RJ, van Katwijk M, Bos JD, Kapsenberg ML. Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol. 1993;150:3643–50.
Ohsaki A, Venturelli N, Buccigrosso TM, Osganian SK, Lee J, Blumberg RS, et al. Maternal IgG immune complexes induce food allergen-specific tolerance in offspring. J Exp Med. 2018;215:91–113. https://doi.org/10.1084/jem.20171163.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
N. Pengo, N. Wuillemin, D. Bieli and P. Gasser are all employees of Mabylon AG which is developing anti-allergen antibody therapies and has patents regarding such products.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Pengo, N., Wuillemin, N., Bieli, D. et al. Anti-allergen monoclonal antibodies for the treatment of allergies. Allergo J Int 32, 289–295 (2023). https://doi.org/10.1007/s40629-023-00263-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40629-023-00263-8